Erik Naylor
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Erik Naylor.
Sleep Medicine | 2010
Kathryn J. Reid; Kelly Glazer Baron; Brandon Lu; Erik Naylor; Lisa A. Wolfe; Phyllis C. Zee
OBJECTIVE To assess the efficacy of moderate aerobic physical activity with sleep hygiene education to improve sleep, mood and quality of life in older adults with chronic insomnia. METHODS Seventeen sedentary adults aged >or=55 years with insomnia (mean age 61.6 [SD±4.3] years; 16 female) participated in a randomized controlled trial comparing 16 weeks of aerobic physical activity plus sleep hygiene to non-physical activity plus sleep hygiene. Eligibility included primary insomnia for at least 3 months, habitual sleep duration <6.5h and a Pittsburgh Sleep Quality Index (PSQI) score >5. Outcomes included sleep quality, mood and quality of life questionnaires (PSQI, Epworth Sleepiness Scale [ESS], Short-form 36 [SF-36], Center for Epidemiological Studies Depression Scale [CES-D]). RESULTS The physical activity group improved in sleep quality on the global PSQI (p<.0001), sleep latency (p=.049), sleep duration (p=.04), daytime dysfunction (p=.027), and sleep efficiency (p=.036) PSQI sub-scores compared to the control group. The physical activity group also had reductions in depressive symptoms (p=.044), daytime sleepiness (p=.02) and improvements in vitality (p=.017) compared to baseline scores. CONCLUSION Aerobic physical activity with sleep hygiene education is an effective treatment approach to improve sleep quality, mood and quality of life in older adults with chronic insomnia.
PLOS ONE | 2010
W. John Sheward; Erik Naylor; Seymour Knowles-Barley; J. Douglas Armstrong; Gillian Brooker; Jonathan R. Seckl; Fred W. Turek; Megan C. Holmes; Phyllis C. Zee; Anthony J. Harmar
Background Diurnal variations in the incidence of events such as heart attack and stroke suggest a role for circadian rhythms in the etiology of cardiovascular disease. The aim of this study was to assess the influence of the suprachiasmatic nucleus (SCN) circadian clock on cardiovascular function. Methodology/Principal Findings Heart rate (HR), blood pressure (BP) and locomotor activity (LA) were measured in circadian mutant (Vipr2 −/−) mice and wild type littermates, using implanted radio-telemetry devices. Sleep and wakefulness were studied in similar mice implanted with electroencephalograph (EEG) electrodes. There was less diurnal variation in the frequency and duration of bouts of rest/activity and sleep/wake in Vipr2 −/− mice than in wild type (WT) and short “ultradian” episodes of arousal were more prominent, especially in constant conditions (DD). Activity was an important determinant of circadian variation in BP and HR in animals of both genotypes; altered timing of episodes of activity and rest (as well as sleep and wakefulness) across the day accounted for most of the difference between Vipr2 −/− mice and WT. However, there was also a modest circadian rhythm of resting HR and BP that was independent of LA. Conclusions/Significance If appropriate methods of analysis are used that take into account sleep and locomotor activity level, mice are a good model for understanding the contribution of circadian timing to cardiovascular function. Future studies of the influence of sleep and wakefulness on cardiovascular physiology may help to explain accumulating evidence linking disrupted sleep with cardiovascular disease in man.
Brain Research | 1998
Etienne Challet; Erik Naylor; Joseph M. Metzger; D. Euan MacIntyre; Fred W. Turek
Substance P (SP) is a neuromodulator which may participate in the photic regulation of the circadian timing system in mammals. The biological effects of SP are mediated by interaction with specific receptors, designated as NK1, NK2, and NK3. The NK1 subtype receptor is expressed in the circadian system. Experiment 1 was designed to test whether an NK1 antagonist mimics the effects of dark pulses. Hamsters were housed in constant lighting conditions, either constant darkness or constant light (around 250 lx), and they received an i.p. injection of either the specific NK1 receptor antagonist, L-760,735 (5 mg/kg), or saline during the mid-subjective day, a time when dark pulses cause a phase-advance in circadian rhythm of locomotor activity. After treatment with the NK1 antagonist, significant phase-advances of wheel-running activity rhythm were found in constant light, but not in constant darkness. Experiment 2 was designed to test the ability of the NK1 antagonist to block the phase-delaying and/or the phase-advancing effects of light in animals kept in constant darkness. Phase-advances of locomotor activity rhythm that can normally be induced by light pulses given during the late subjective night were markedly reduced by pre-treatment with the NK1 antagonist. By contrast, phase-delays that can be induced by lights pulses given during the early subjective night were unaffected by the NK1 antagonist. These data support the hypothesis that SP within the circadian system may, by interacting with NK1 receptors, modulate photic responses of the SCN pacemaker.
The Journal of Neuroscience | 2000
Erik Naylor; Bernard M. Bergmann; Kristyn Krauski; Phyllis C. Zee; Joseph S. Takahashi; Martha Hotz Vitaterna; Fred W. Turek
Sleep | 2000
Erik Naylor; Plamen D. Penev; Larry Orbeta; Imke Janssen; Rosemary Ortiz; Egidio F. Colecchia; Moses Keng; Sanford I. Finkel; Phyllis C. Zee
Sleep | 1998
Erik Naylor; Orfeu M. Buxton; Bernard M. Bergmann; Amy Easton; Phyllis C. Zee; Fred W. Turek
Sleep Medicine Clinics | 2006
Erik Naylor; Phyllis C. Zee
Archive | 2009
David A. Johnson; Erik Naylor; Hans Harmon; Seth Gabbert
Archive | 2009
Erik Naylor; Hans Harmon; Seth Gabbert; David A. Johnson
Archive | 2009
Erik Naylor; Daniel V. Aillon; Seth Gabbert; Hans Harmon; Donna A. Johnson; George S. Wilson; Peter A. Petillo; David A. Johnson